Lantern is a leader in the development of tech-bio to deliver the next generation of cancer medicines, where success is defined by both AI-driven progress and meaningful patient outcomes," said Panna ...

Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication ...

The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of results from the CardiAMP HF Trial at the Late-Breaking Clinical Trials ...

vTv Therapeutics, a biopharmaceutical company based in High Point, has received clearance from the U.S. Food and Drug ...

Avant Technologies Inc. (OTCQB:AVAI) (”Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

A data management framework for multisite randomized longitudinal clinical trials. Here are a set of python modules that extend Django to empower you to build an EDC / eSource system to handle data ...

ACT: Considering the findings from the Barriers in Clinical Trials survey, what are some new opportunities for medical research to accelerate drug development? Ross: I think that when you think about ...

Increasingly, protocol stack development is subjected to constant requirements changes arising from evolving technical standards, changing customer needs and diverse deployment scenarios coupled with ...

--(BUSINESS WIRE)--TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development and progression ...

These advancements help sponsors create more efficient, compliant, and patient-friendly trials. Driven by technology, innovations in protocol authoring have allowed pharmaceutical companies to adopt ...